Next-generation imaging development for nanoparticle biodistribution measurements.
暂无分享,去创建一个
[1] Shelton D Caruthers,et al. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. , 2006, Nanomedicine.
[2] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[3] Donghoon Lee,et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.
[4] James J. Driscoll,et al. Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.
[5] Shelton D Caruthers,et al. Nanomedicine strategies for molecular targets with MRI and optical imaging. , 2010, Future medicinal chemistry.
[6] Lesley Seymour,et al. Tumor Shrinkage and Objective Response Rates: Gold Standard for Oncology Efficacy Screening Trials, or an Outdated End Point? , 2009, Cancer journal.
[7] R Sankar,et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy , 2008, Neurology.
[8] I-Chih Tan,et al. Lymphatic imaging in humans with near-infrared fluorescence. , 2009, Current opinion in biotechnology.
[9] S. Nofech-Mozes,et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? , 2010, Gynecologic oncology.
[10] M. Kashani-Sabet,et al. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. , 2010, Journal of the American Academy of Dermatology.
[11] Ciprian Catana,et al. Bimodal MR-PET agent for quantitative pH imaging. , 2010, Angewandte Chemie.
[12] Jurgen Seidel,et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. , 2009, Bioconjugate chemistry.
[13] Dorothy Farrell,et al. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[14] K. Washington,et al. Assessment of Hepatic Steatosis by Expert Pathologists: The End of a Gold Standard , 2009, Annals of surgery.
[15] Angelique Y. Louie,et al. Core/shell quantum dots with high relaxivity and photoluminescence for multimodality imaging. , 2007 .
[16] James R Baker,et al. Dendrimer-based nanoparticles for cancer therapy. , 2009, Hematology. American Society of Hematology. Education Program.
[17] Kerry K. Karukstis,et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.
[18] Marcelino Bernardo,et al. A dendrimer‐based nanosized contrast agent dual‐labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice , 2007, Journal of magnetic resonance imaging : JMRI.